Longbio Pharma
Clinical trials sponsored by Longbio Pharma, explained in plain language.
-
New injection shows promise for rare kidney disease
Disease control Not yet recruitingThis study tests an experimental drug called LP-005 for people with kidney disease caused by an overactive immune system (complement system). The drug is given as an injection alongside standard care. About 46 adults aged 18-65 will take part to see if it helps control kidney dam…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 17, 2026 05:22 UTC
-
New hope for PNH patients: LP-005 injection tested for Long-Term control
Disease control Not yet recruitingThis study is for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have already completed a previous LP-005 trial. It aims to see if the LP-005 injection is safe and works well over a longer period. About 30 people will take part, and researchers will monitor side effect…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
New injection could shrink nasal polyps and ease breathing
Disease control Not yet recruitingThis study tests an experimental drug called LP-003 for people with chronic sinusitis and nasal polyps (growths in the nose). The goal is to see if it can shrink polyps and reduce stuffiness. About 150 adults will receive either the drug or a placebo, and their progress will be t…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated May 17, 2026 05:04 UTC